LAUREN HARR: Open Payments
NPI 1013393669 · FORT WORTH, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,818 in 118 payments from 20 companies in 2025. Trend: 2023 $3,223 · 2024 $3,001 · 2025 $2,818
Food & beverage: $2,818
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 10 | $391 |
| Regeneron Healthcare Solutions, Inc. | 15 | $391 |
| UCB, Inc. | 16 | $384 |
| Novartis Pharmaceuticals Corporation | 10 | $302 |
| Arcutis Biotherapeutics, Inc. | 17 | $260 |
| MERZ NORTH AMERICA, INC. | 2 | $170 |
| Galderma Laboratories, L.P. | 11 | $167 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 5 | $137 |
| Almirall LLC | 6 | $120 |
| ABBVIE INC. | 5 | $96 |
Products named: DUPIXENT, Bimzelx, Zoryve, Rhapsido, Xeomin, NEMLUVIO, LIBTAYO, Klisyri.
Industry payments across TX — which companies pay providers there.
